Radioactive tracer reveals how potential Crohn's drug moves through the body
NCT ID NCT07672574
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial in 8 healthy men aged 30–65 examines how the body absorbs, breaks down, and eliminates ontunisertib, an experimental oral drug for fibrostenotic Crohn's disease. Participants receive a single dose of the drug with a radioactive label, allowing researchers to track its path and measure how much leaves the body through urine and stool. The goal is to understand the drug's metabolism and absolute bioavailability, which will guide future dosing in patient studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ontunisertib (AGMB-129)
- What this could lead to
- If successful, this could help determine the right dose of ontunisertib for future trials in people with fibrostenotic Crohn's disease.
- What could go wrong
- This is an early-phase study in only 8 healthy men, not patients. It focuses on drug processing, not on treating disease, so results may not predict effectiveness or safety in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSTENOTIC CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quotient Sciences Limited
Nottingham, NG11 6JS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.